Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05048251 · ClinicalTrials.gov registry record · NA

Individually Targeted Neuromodulation for Contamination-based OCD

A NA study of Obsessive - Compulsive Disorder, sponsored by Mclean Hospital.

Recruiting
Registry status
NA
Development phase
50
Enrollment target
1
Study location

NCT05048251 is a NA study of Obsessive - Compulsive Disorder that is actively recruiting participants, run by Mclean Hospital. The registered enrollment target is 50 participants, below the 2,064-participant average among 84 other Obsessive - Compulsive Disorder trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05048251, a NA study of Obsessive - Compulsive Disorder, is actively recruiting participants, sponsored by Mclean Hospital.

RECRUITING
Registry status
NA
Development phase
50 participants
Enrollment target
1
Study location

Study Summary

Patients with obsessive-compulsive disorder (OCD) experience a wide array of different types of obsessions and compulsions. However, current treatments for OCD employ a "one size fits all" approach and are used for all patients regardless of symptom type. In this project, the investigators propose to investigate whether a novel method of transcranial magnetic stimulation specifically reduces contamination/washing symptoms - one of the most common types of OCD.

Interventions

  • DEVICE iTBS
  • DEVICE cTBS
  • DEVICE sham

Study Locations (1)

Massachusetts

  • McLean Hospital - Belmont

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2022-07-01
Est. Completion 2024-06-30
Phase NA

Sponsor

Mclean Hospital

140 total trials

What the Registry Record Tells You About NCT05048251

The ClinicalTrials.gov registry entry for NCT05048251 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,064-participant average among 84 other Obsessive - Compulsive Disorder trials with a reported enrollment target (98% lower). The listed sponsor is Mclean Hospital, which has 140 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Obsessive - Compulsive Disorder appearing as the primary indexed condition, and to 3 interventions - of which iTBS is the first listed.

NCT05048251 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT05048251 about?

NCT05048251 is a clinical study titled "Individually Targeted Neuromodulation for Contamination-based OCD". Patients with obsessive-compulsive disorder (OCD) experience a wide array of different types of obsessions and compulsions. However, current treatments for OCD employ a "one size fits all" approach and are used for all patients regardless of symptom type. In this project, the investigators propose t...

What is the current status of trial NCT05048251?

This trial is currently recruiting. It is a NA study. The enrollment target is 50 participants. The study started on 2022-07-01. Estimated completion is 2024-06-30.

What conditions does trial NCT05048251 study?

This clinical trial studies the following conditions: Obsessive - Compulsive Disorder.

What interventions are being tested in trial NCT05048251?

The interventions under investigation include: iTBS (DEVICE), cTBS (DEVICE), sham (DEVICE).

Who is sponsoring clinical trial NCT05048251?

This trial is sponsored by Mclean Hospital, which has 140 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05048251 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Obsessive - Compulsive Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.